Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis?

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 4, 2004, Pages 955-958

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

Alendronate; Bone mineral density; Clinical trial; Osteoporosis; Parathyroid hormone

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; MULTIVITAMIN; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; PLACEBO; RECOMBINANT HORMONE; TILUDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL STUDY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; FRACTURE; GENDER; GOUT; HUMAN; HYPERCALCEMIA; HYPERURICEMIA; INCIDENCE; MONOTHERAPY; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; SIDE EFFECT; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

ALENDRONATE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE;

EID: 1842843688     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.4.955     Document Type: Article

References (13)

1. BLACK DM, GREENSPAN SL, ENSRU KE et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. (2003) 349:1207-1215.
2. FINKELSTEIN JS, HAYES A, HUNZELMAN JL et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. (2003) 349:1216-1226.
3. SIRIS ES, MILLER PD, BARRETT-CONNOR E et al.: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. JAMA (2001) 286:2815-2822.
4. MESSINGER-RAPPORT BJ, THACKER HL: Prevention for the older women, part 3: A practical guide to prevention and treatment of osteoporosis. Geriatrics (2002) 57:16-27.
5. LIBERMAN UA, WEISS RR, BRÖLL J et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. (1995) 333:1437-1443.
6. ORWOLL E, ETTINGER M, WEISS S et al.: Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. (2000) 343:604-610.
7. RITTMASTER RS, BOLOGNESE M, ETTINGER MP et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. (2000) 85:2129-2134.
8. NEER RM, ARNAUD CE, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344:1434-1441.
9. KURLAND ES, COSMAN F, MCMAHON DJ et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J. Clin. Endocrinol. Metab. (2000) 85:3069-3076.
10. ORWOLL ES, SCHEELE WH, PAUL S et al.: The effect of teriparatide [human parathyroid hormone (1-34)] on bone density in men with osteoporosis. J. Bone Miner. Res. (2003) 18:9-17.
11. 1-34] is not retarded by long-term treatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology (2003) 144:2008-2015.
12. LINDSAY R, NIEVES J, FORMICA C et al.: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 350:550-555.
13. DELMAS OD, VERGNAUD P, ARLOT ME et al.: The anabolic effect of human PTH (1-34) on bone formation is blunted by the bisphosphonate tiludronate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system. Bone (1995) 350:550-555.